Abstract: After a lull in development of new chemistry for rhenium-188 and technetium-99m since 2000, there has been new investment in production facilities for Mo-99/Tc-99m coupled with increasing interest in rhenium-188 radionuclide therapy, particularly in developing countries. Much of the chemistry developed in the 1990s is not readily amenable to supporting modern radiopharmaceutical development, which places increased emphasis on molecular targeted radiopharmaceuticals. Consequently there is a need for new radiolabelling chemistry to incorporate these radionuclides into biomolecules using simple, kit-based methodology. This review provides an update on progress towards simple rhenium-188 labelling methods since 2000.
INTRODUCTION
The rhenium-188 generator is an attractive source of a therapeutic radionuclide, for a variety of reasons, in certain settings and applications. It can provide daily availability, by a simple elution process entirely analogous to the elution of a technetium-99m generator. The capital cost (i.e. purchase of a generator) may be high but in a setting where many patients can be treated, it can be very economical compared to commercially available batch-produced therapeutic radionuclides such as lutetium-177. It is, in principle at least, versatile and can be incorporated into a range of types of vehicle suitable for molecular targeting. Its β-energy is high E max 2.21 MeV, comparable to that of phosphorus-32 and yttrium-90), delivering a high radiation dose, and the half-life of 17 hours is compatible with the pharmacokinetics of many small molecules and antibody fragments. Its low abundance gamma emissions (155 KeV, 15%) allow gamma camera imaging. These properties are less favourable in some circumstances; for example, the high energy β-emission is not likely to be effective in eradicating smaller tumours and micrometastases, and the 17 hour half-life is too short to be fully compatible with the pharmacokinetics of whole IgG antibodies whose blood half-life is typically several days. Nevertheless, the favourable logistics and economics associated with generator-based availability make it very attractive, particularly in locations where these features are particularly important, such as economically less developed countries.
The development of the chemistry of 188 Re radiopharmacueticals has to an extent shadowed that of 99m Tc, with which its coordination chemistry is highly analogous by virtue of its periodic position [1] . The analogy includes the chemical basis of the generatorboth rely on β-decay of MO 4 2-(M = 99 Mo or 188 W) to give MO 4 -(M =
Tc or 188 Re), which is more readily eluted from the alumina solid phase by saline. The development of the chemistry of 99m Tc radiopharmacueticals since the 1960s, following the advent of the 99 Mo/ 99m Tc generator and the gamma camera, can be traced in three phases.
The first phase comprises radiopharmaceuticals coming into routine use in the 1970s, such as the complexes of dimercaptosuccinic acid (DMSA), bisphosphonates (e.g. methylene diphosphonate, MDP), diethylenetriamine pentaacetic acid (DTPA) and glucoheptonate. The development of these was based on almost no knowledge of the basic coordination chemistry of technetium, and in most cases the molecular structures and oxidation states of the technetium in these radiopharmaceuticals remain unknown even today. Indeed, they are likely to be complex mixtures of structures. This early phase was characterised by very little understanding of either technetium chemistry or the mechanisms by which the specific targeting of the tracers occurred in vivo. Hence their nuclear medicine utility is best described as "functional imaging."
In the second phase emerging in the 1980s, new 99m Tc radiopharmaceuticals with well-defined structure appeared, building on new basic research in technetium chemistry by pioneers such as Davison and Deutsch. This research led to identification of the more stable "technetium core" complex types in which ligand design was well-matched to the coordination preferences of the metal in its different oxidation states. The third phase, emerging in the 1990s, coincided with the transition of nuclear medicine into the age of "molecular imaging" in which specific molecular pathways and receptors began to be targeted with specifically designed radiopharmaceuticals, often based on bioconjugates, in order to answer specific biomedical questions. Up Tc to cysteine thiolate groups generated by reduction of antibody disulfide bonds) have been developed and available since the 1990s, but they have made little clinical impact. This may be in part because, unlike the phase 1 and 2 99m Tc radiopharmaceuticals, which were amenable to onestep kit formulation and reconstitution, none of the phase 3 labelling methods are technically easy and efficient to perform. In addition, it may be in part because the period since 1990 has coincided with the expansion of clinical PET, with research and development funds both in industry and academia being redirected towards molecular imaging with positron emitters. Re-bisphosphonate complexes, of unknown and heterogeneous structure, were the first to emerge in clinical application (palliative treatment of painful bone metastases in prostate cancer). The first structurally well-characterised example was the pentavalent 188 Re-DMSA complex, with potential application in radionuclide therapy of medullary thyroid carcinoma and bone metastases in prostate cancer, which also emerged in the 1990s, [4] [5] [6] [7] along with use of the 188 Re-MAG3 complex as a soluble β-emitting agent to fill balloons in coronary angioplasty (aiming to prevent restenosis) to guarantee rapid renal excretion in the event of balloon rupture [8] . Tc, most of these agents and methods were established in the 1990s and although clinical applications have begun to take hold (all of which are based on "phase 1" and "phase 2" chemistry described above, as illustrated in other contributions to this issue), little new 188 Re chemistry development has occurred since that time. This unfortunate trend is reflected in the chart shown in Figure 1, Tc. These developments give credence to the notion and technetium radiopharmaceuticals are here to stay, for the foreseeable future. Alongside the recent growth in adoption of 188 Re radionuclide therapies in some countries, [9, 10] 
188
Re generator availability is improving again and the scene is set for a resurgence of development of both 99m Tc and 188 Re chemistry development, reversing the recent trend (see Figure 1 ) that has seen the collapse of basic research on the chemistry of these radionuclides since 2000. The most comprehensive review of 188 Re radiopharmaceutical chemistry dates back to 1999 [11] and the reader is referred to that review for a summary of the state-of-the-art pre-2000, as well as to reviews published within the last decade covering bifunctional chelator and bioconjugation development for labelling peptides and proteins with both 99m Tc and 188 Re [12] [13] [14] . The purpose of this article is to provide a brief update of developments since that time, identifying limitations of well-established coordination chemistry, with a focus on novel and well-characterised chemistry that has potential for application in the modern age of molecular imaging, rather than clinical applications of older, less well-characterised 188 Re agents, particulate and non-molecular materials (such as nanoparticles, liposomes, emulsions, stents and patches) and antibodies labelled using older methods.
DISCUSSION

Rhenium (V) Complexes
has been evaluated as a means of direct attachment to amino acid side chains of antibodies and peptides containing cysteine-thiol groups, often generated by reduction of disulfide bonds. This has become a mainstay of labelling whole antibodies after reduction of inter-chain disulfide bonds, offering versatile applicability and moderate stability of the labelled protein [11] . However, in the context of smaller proteins and antibodies where the structural impact of labelling is greater, use of native amino acid backbone and side chain donor groups (amide and thiolate) to bind the [ReO] 3+ core (and its Tc analogue) directly has been problematic; either they are poorly characterised [15] or studies using mass spectrometry and molecular modelling have shown that it leads to heterogeneous mixtures of multiple isomers and monomeric and dimeric structures [16] [17] [18] [19] . This direct labelling approach is therefore not recommended as a strategy for peptide labelling. Bifunctional chelators designed to accommodate the structural preferences of the [ReO] 3+ offer a more reliable strategy. Use and further design [20] of tetradentate ligands containing a combination of amino/amido and thiolate donors [21] such as MAG3 [22] (Figure 3a) and cysteine-containing amino acid sequences [23, 24] (Figure 2) , developed in the 1990s, [11] have remained popular for attachment to lipids [25, 26] and peptides, [22, [27] [28] [29] [30] [31] [32] or simple complexes designed for rapid renal excretion in the context of radionuclide therapy during balloon angioplasty, [33, 34] Re analogues were synthesised and shown to have identical structure and isomerism [6, 7] (Figure 3b ) and biodistribution (targeting medullary thyroid carcinoma and bone metastases in prostate, lung and breast cancer) [4, 5] . The simple synthesis of the 188 Re complexes and wide interest in these applications led to development of kit-based labelling, [37, 38] and preclinical evaluation in normal mice [39, 40] and in other tumours (e.g. cervical carcinoma models [41] ). Further study showed that the individual isomers showed no significant differences in biodistribution, and underwent interconversion, in rats [42] and (in the case of [ 99m TcO(DMSA) 2 ] -) in humans [43] . The analogous complexes of the racemic DMSA ligand (Figure 3c) were evaluated [44] in PC-12 tumours in nude mice and showed higher tumour uptake than the meso- complexes. A range of ester derivatives of the complexes showed promising tumour uptake and reduced bone uptake in animal models [45] .
The high stability in vivo in humans, [5] Re complexes readily (by direct reduction of perrhenate in the presence of the ligand). The complexes showed very high resistance to ligand exchange reactions in plasma, and can be linked to targeting molecules via the central amino group; however, the problem of multiple isomers persists [47, 48] .
A ligand system specifically designed to accommodate the [ReO] 3+ core, offering high symmetry, is the bhci system (Figure 3f ) which is pentadentate, differing from most other ligand sets in filling the position trans to the oxo-ligand and thus removing an associative pathway for ligand substitution and oxidation to perrhenate. It was conjugated to an antibody via the non-coordinated amino group using an N-hydroxysuccinimide active ester, but despite the excellent thermodynamics and kinetics of its [ReO] 3+ coordination capacity, it still had to pre-labelled with 188 Re before conjugation to the antibody [49] .
+ has also been suggested as the basis of bioconjugates; carbene complexes of the dioxo core proved insufficiently stable for radiopharmaceutical use, [50] but placing this core within a tetraamine ligand set, provided by two ethylene diamine ligands or one linear or cyclic tetramine (Figure 4a) , has been shown to provide excellent stability against ligand exchange and oxidation in serum, with moderately convenient aqueous synthesis (entailing reduction with stannous chloride in the presence of the ligand), except in the case of cyclic ligands such as cyclam where kinetic barriers to complexation were high [51] . Electrochemical studies showed that although the ethylene diamine complex is vulnerable to reduction when protonated, the 1,4,7,10-tetrazaundecane complex is not [52] . Neither optimisation to make radiolabelling more efficient and convenient, nor incorporation into bioconjugates, has been attempted, however. This approach was subsequently adopted for 99m Tc and shown to be highly promising for labelling of bioconjugates using the 1,4,7,10-tetrazaundecane rhenium dioxo-complex (Figure 4b) , offering both mild and simple aqueous radiolabelling, high symmetry and excellent stability under biological conditions [53] . If satisfactory optimisation of the 188 Re-labelling procedure can be achieved, including perhaps selection of a more suitable reducing agent than stannous chloride, this potentially offers a simple solution to the problem of forming a stable bioconjugates without problems of isomerism and multi-step synthesis, and could lead to a "matched pair" theranostic combination of analogous 99m Tc and 188 Re radiopharmaceuticals.
The [ReO 2 ]
+ core is made all the more attractive as a direction for further research by the observation that bis(amido)bis(phosphine) [54] and bis(thioether)-bisphosphine) [55] ligands (Figure 4) [57] its pegylated derivative (HO 2 C-PEG(600)-DTCZ) [58] and succinic dihydrazide, with the former preferred as the most generally useful and efficient. The reaction produces an intermediate rhenium nitride complex which is subsequently treated with a suitable ligand combination to produce the final (usually square pyramidal) complex. Ligand sets employed include a symmetrical pair of dithiocarbamates [57, 59, 60] or dithiocarboxylates, [61] or unsymmetrical combinations of aminodiphosphine (PNP) with a bidentate thiolate [58, 62] or a monodentate tertiary phosphine with a tridentate dithiolate derived from two cysteine residues appended to a peptide ( Figure 5 ) [63] . The bis(dithiocarbamate) is most simply used as the basis of a divalent targeting agent, such as the bis(bisphosphonate) derivatives developed as potential therapeutic radiopharmaceuticals for bone metastases [60] . Although the [ReN] 2+ system is stable and potentially versatile, the multi-step nature of the labelling process means it is unlikely to find widespread utility in its present form.
A bifunctional chelator that has been successful for 99m
Tc labeling of biomolecules is hydrazinonicotinamide (HYNIC) (Figure 6) . It offers probably the most efficient and highest specific activity methods for labelling peptides and proteins, but is limited by the need for a set of co-ligands to complete the 99m Tc coordination sphere and the consequent problem of formation of mixtures of isomers, each with potentially different biodistribution [64] . Although usually depicted with monodentate diazenido ligands, all physical evidence, coupled with knowledge of the structure of model complexes, suggests that the HYNIC is a bidentate chelating ligand forming Tc(V) complexes (Figure 6 ) [64] [65] [66] . Despite much of this structural evidence arising from analogy to known stable rhenium complexes, [64] attempts to use HYNIC as a bifunctional chelator for 188 Re [67] have met with failure and the conditions required to form labelled complexes with structure and stability analogous to the 99m Tclabelled HYNIC-biomolecule conjugates are yet to be discovered. Extension of HYNIC with a thioamide tethering group provides a modification that gives a stable, well-defined chelated derivative with the square pyramidal [ReO] 3+ core [68] and can be radiolabelled with 188 Re in this form (Figure 6 ) [69] .
Rhenium (I) Complexes
The proteins are histidine residues and this has been particularly useful for labelling recombinant proteins that incorporate histidine tags (a sequence of typically six consecutive histidine residues) as a purification tool. Proteins without histidines, or with only isolated histidines, label poorly [75] whereas those with oligohistidine sequences can be labelled relatively efficiently [76] . Studies aimed at identifying optimal histidine-containing sequences for labelling with [Re(CO) 3 ] + have shown that as well as multiple histidines, incorporation of cysteine [77] or methionine [70, 78] residues into the sequence can enhance labeling efficiency and stability, and incorporation of positively charged amino acids (arginine, lysine) is particularly effective, with the potential to improve specific activity and avoid the need for post-labelling purification steps [78] . Although at least two histidine imidazole groups are assumed to bind to the rhenium, the full make-up of the coordination sphere when [Re(CO) 3 ] + is bound to histidine tags is unknown. The Several synthetic, usually tridentate, bifunctional chelators have been used to link the tricarbonyl fragment to biomolecules. Most common is dipyridyl (DPA, Figure 7b) 51 [72, [80] [81] [82] but related structures including picolinic acid derivatives, [83, 84] tridentate pyrazolyl ligands, [85] aminodiacetate, [86] triazoles, [87] [88] [89] histidine derivatives [89] [90] [91] and pyrimidines [92] have been reported. Carboxylate and ester derivatives of the cyclopentadienyl ligand (Figure 7c) 6 ] + where CNR = 2-methoxyisobutylisonitrile) has been reported but no evidence that the complex produced has the reported structure was provided [99] . coordinated by a ligand set of six sulfur atoms comprising two trithioperoxy and one dithiocarboxylate ligand (Figure 8b) [102] . The dithiocarboxylate ligand can be replaced by dithiocarbamates to give more stable complexes containing two trithioperoxy ligands and a dithiocarbamate, which could become the basis of a bioconjugate (Figure 8) . These complexes are readily synthesised from Re(V) oxo precursors but synthesis direct from perrhenate has yet to be explored [103] .
Rhenium (III) Complexes
Trigonal bipyramidal Re(III) complexes with a tetradentate aminotrithiolate ligand and a π-acceptor ligand such as an isonitrile or phosphine (Figure 8c) are accessible efficiently in a two stage process from perrhenate via a Re-EDTA complex formed by stannous reduction of perrhenate in the presence of EDTA. By incorporation of a carboxylate side chain into the tetradentate ligand (Figure 8 ) synthesis of bioconjugates based on this core structure is feasible [104] .
An intriguing and unusual set of complexes in a range of oxidation states is made possible by use of the 1,4,7-trithiacyclononane ligand (9S3 (Figure 8d ). This sequence of reactions can be performed, and the 188 Re product isolated, within a few minutes with 188 Re generator eluate, [105, 106] but has not been developed into a system for 188 Re-bioconjugate synthesis.
Rhenium (VII) Complexes
The possibility of finding chelators that will stabilise the Tc(VII) trioxo core [ Re]perrhenate irradiates NISexpressing cells from the inside rather than the outside, and this offers a microdosimetric advantage that could result in higher cytotoxicity [125] . It may also be advantageous in non-thyroid tumours expressing NIS, because its lack of metabolism means that its retention in normal thyroid tissue will be lower and hence its availability for uptake in non-thyroidal NIS-expressing cells will be greater than that of [ Tc production, coupled with a resurgence of interest in use of the 188 Re generator in less developed countries, should ignite a reawakening of development of new chemistry to support use of both radionuclides in the new age of molecular imaging and targeted radionuclide therapy. Current clinical use of 188 Re radionuclide therapy relies entirely on chemistry developed in the 1990s and earlier, and new chemistry to facilitate use of specific molecular targeted biomolecules is needed. In particular, chemistry to exploit the use of generatorproduced 188 Re on the hospital site is needed, and this requires chemical methodology that is simple and kitbased to minimise the requirement for costly infrastructure. This in turn needs chemistry to convert 188 Re from perrhenate to the required radiopharmaceutical, rapidly, under mild conditions compatible with biomolecules, preferably in a single step and without need for post-labelling purification, to produce a single stable homogeneous labelled product free of isomerism. The chemistry reported in this and previous reviews does not fully meet these challenges. Chemists must be imaginative and innovative to design new chelating systems and rhenium "cores" and discover reducing agents other than stannous salts to reduce perrhenate, in order to meet these challenges in the coming years.
MISCELLANEOUS RHENIUM COMPLEXES WITH UNKNOWN OXIDATION STATE
